78 results
8-K
EX-99.1
ZVRA
Zevra Therapeutics Inc
8 May 24
Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
7:54am
statements regarding the potential benefits of our debt facility, our cash balance, our corporate governance objectives, potential revenues from our
DEFA14A
ZVRA
Zevra Therapeutics Inc
29 Apr 24
Additional proxy soliciting materials
7:49am
area: Audit, Compensation, and Nominating and Corporate Governance. Also, the Board will leverage feedback from its self-evaluation process, which … benefits of our debt facility, our cash balance, our corporate governance objectives, potential revenues from our arimoclomol expanded access program
424B3
8shvvibzouizp5 4xr
10 Oct 23
Prospectus supplement
5:07pm
S-4/A
bbiehh ok
6 Oct 23
Registration of securities issued in business combination transactions (amended)
4:06pm
S-4
jgx8gybkrlt66yfq2
28 Sep 23
Registration of securities issued in business combination transactions
9:25pm
425
dvc35d5vsb yld3
31 Aug 23
Business combination disclosure
8:03am
8-K
EX-2.1
a62z fowjabuy
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
424B3
9pb8kxd
10 Nov 21
Prospectus supplement
5:19pm
424B3
t2z40gjx468j9
19 Oct 21
Prospectus supplement
9:27am